<DOC>
	<DOCNO>NCT00509613</DOCNO>
	<brief_summary>The purpose trial identify recommend dose sorafenib sirolimus combination therapy subsequent phase 2 trial .</brief_summary>
	<brief_title>Phase 1 Study With Sorafenib Sirolimus</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients histological cytological confirm advanced solid tumor , refractory standard therapy standard therapy exists rationale therapeutic use combination sorafenib sirolimus ( especially metastic RCC , malignant melanoma , HCC , NSCLC , pancreatic cancer , hormone refractory prostate cancer ) . Men woman least 18 year Patients ECOG status 0 1 Patients life expectancy least 12 week Adequate bone marrow , liver renal function Negative pregnancy test female patient childbearing potential Women men enrol trial must use adequate birth control measure course trial . Signed informed consent History serious cardiac disease Active clinically serious bacterial , viral fungal infection ( &gt; grade 2 ) . Known history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C. Clinically symptomatic brain meningeal metastasis . Patients seizure disorder require medication ( steroids antiepileptic ) . Patients evidence history bleed diathesis . Substance abuse , medical , psychological social condition may interfere patient participation study evaluation study result . Concomitant treatment strong CYP3A4 inductor ( rifampicin , St. JohnÂ´s Wort ) CYP3A4 inhibitor ( ketoconazole , voriconazole , itraconazole , diltiazem , verapamil , erythromycin ) . Moderate weak CYP3A4 modifier use concomitantly careful assessment riskbenefit ratio . Concomitant use carbamazepine , phenobarbital , phenytoin chronic use dexamethasone exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>